Details

Autor(en) / Beteiligte

• Liu, C.‐H.
• Sun, H.‐Y.
• Liu, C.‐J.
• Sheng, W.‐H.
• Hsieh, S.‐M.
• Lo, Y.‐C.
• Liu, W.‐C.
• Su, T.‐H.
• Yang, H.‐C.
• Hong, C.‐M.
• Tseng, T.‐C.
• Chen, P.‐J.
• Chen, D.‐S.
• Hung, C.‐C.
• Kao, J.‐H.

Titel

Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection

Ist Teil von

• Alimentary pharmacology & therapeutics, 2018-06, Vol.47 (12), p.1690-1698

Ort / Verlag

England: Wiley Subscription Services, Inc

Erscheinungsjahr

2018

Quelle

Wiley Online Library

Beschreibungen/Notizen

• Summary Background Data are limited regarding the effectiveness and safety of generic velpatasvir plus sofosbuvir (VEL/SOF) for hepatitis C virus (HCV) in patients with or without human immunodeficiency virus (HIV) coinfection. Aim To evaluate the effectiveness and safety of generic VEL/SOF‐based therapy for HCV infection in patients with or without HIV coinfection in Taiwan. Methods Sixty‐nine HIV/HCV‐coinfected and 159 HCV‐monoinfected patients receiving 12 weeks of generic VEL/SOF with or without ribavirin (RBV) for HCV were prospectively enrolled. The anti‐viral responses and the adverse events (AEs) were compared between the two groups. The characteristics potentially related to sustained virological response 12 weeks off therapy (SVR12) were analysed. Results The SVR12 was achieved in 67 HIV/HCV‐coinfected patients (97.1%; 95% CI: 90.0%‐99.2%) and in 156 HCV‐monoinfected patients (98.1%; 95% CI: 94.6%‐99.4%) receiving VEL/SOF‐based therapy, respectively. The SVR12 rates were comparable between HIV/HCV‐coinfected and HCV‐monoinfected patients, regardless of pre‐specified baseline characteristics. One hundred twenty‐two (53.5%) and seven (3.1%) patients had baseline resistance‐associated substitutions (RASs) in HCV NS5A and NS5B regions, but the SVR12 rates were not affected by the presence or absence of RASs. One (1.4%) and five (3.1%) patients in the HIV/HCV‐coinfected and HCV‐monoinfected groups had serious AEs. No patient died or discontinued treatment due to AEs. The eGFR remained stable throughout the course of treatment in HIV/HCV‐coinfected patients receiving anti‐retroviral therapy containing tenofovir disoproxil fumarate (TDF). Conclusions Generic VEL/SOF‐based therapy is well‐tolerated and provides comparably high SVR12 rates for HCV infection in patients with and without HIV coinfection.